The diagnostic challenges of functioning neuroendocrine tumors: balancing accuracy, availability, and personalized care

References

• Pathak S, Starr JS, Halfdanarson T, et al. Understanding the increasing incidence of neuroendocrine tumors. Expert Rev Endocrinol Metab. 2023 Sep-Nov;18(5):377–385. doi: 10.1080/17446651.2023.2237593. Epub 2023 Jul 19. PMID: 37466336.
   PubMed Web of Science ®Google Scholar
• Rossi RE, Massironi S. The increasing incidence of neuroendocrine neoplasms worldwide: current knowledge and open issues. J Clin Med. 2022;11(13):3794. doi: 10.3390/jcm11133794
   PubMed Web of Science ®Google Scholar
• Magi L, Marasco M, Rinzivillo M, et al. Management of functional pancreatic neuroendocrine neoplasms. Curr Treat Options Oncol. 2023;24(7):725–41. doi: 10.1007/s11864-023-01085-0
   PubMed Web of Science ®Google Scholar
• Massironi S, Conte D, Rossi RE. Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules. Scand J Gastroenterol. 2016;51(5):513–23. doi: 10.3109/00365521.2015.1115117
   PubMed Web of Science ®Google Scholar
• Rossi RE, Elvevi A, Citterio D, et al. Gastrinoma and Zollinger Ellison syndrome: a roadmap for the management between new and old therapies. World J Gastroenterol. 2021;27(35):5890–907. doi: 10.3748/wjg.v27.i35.5890
   PubMed Web of Science ®Google Scholar
• Partelli S, Massironi S, Zerbi A, et al. Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm: interim analysis of prospective ASPEN trial. Br J Surg. 2022;109(12):1186–90. doi: 10.1093/bjs/znac267
   PubMed Web of Science ®Google Scholar
• Partelli S, Ramage JK, Massironi S, et al. Management of asymptomatic sporadic nonfunctioning pancreatic neuroendocrine neoplasms (ASPEN) ≤2 cm: study protocol for a prospective observational study. Front Med. 2020;7:598438. doi: 10.3389/fmed.2020.598438
   Web of Science ®Google Scholar
• Falconi M, Eriksson B, Kaltsas G, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103(2):153–71. doi: 10.1159/000443171
   PubMed Web of Science ®Google Scholar
• Koffas A, Giakoustidis A, Papaefthymiou A, et al. Diagnostic work-up and advancement in the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. Front Surg. 2023;10:1064145. doi: 10.3389/fsurg.2023.1064145
   PubMed Web of Science ®Google Scholar
• Hofland J, Zandee WT, de Herder WW. Role of biomarker tests for diagnosis of neuroendocrine tumours. Nat Rev Endocrinol. 2018;14(11):656–69. doi: 10.1038/s41574-018-0082-5
   PubMed Web of Science ®Google Scholar
• Modlin IM, Moss SF, Gustafsson BI, et al. The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant. Langenbecks Arch Surg. 2011;396(8):1145–56. doi: 10.1007/s00423-011-0794-7
   PubMed Web of Science ®Google Scholar
• Massironi S, Rossi RE, Casazza G, et al. Chromogranin a in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution. Neuroendocrinology. 2014;100(2–3):240–9. doi: 10.1159/000369818
   PubMed Web of Science ®Google Scholar
• Fuksiewicz M, Kowalska M, Kolasińska-Ćwikła A, et al. Prognostic value of chromogranin a in patients with GET/NEN in the pancreas and the small intestine. Endocr Connect. 2018;7(6):803–10. doi: 10.1530/EC-18-0059
   PubMed Web of Science ®Google Scholar
• Matar S, Malczewska A, Oberg K, et al. Blood chromogranin a is not effective as a biomarker for diagnosis or management of bronchopulmonary neuroendocrine tumors/neoplasms. Neuroendocrinology. 2020;110(3–4):185–97. doi: 10.1159/000500202
   PubMed Web of Science ®Google Scholar
• Marotta V, Zatelli MC, Sciammarella C, et al. Chromogranin a as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame. Endocr Relat Cancer. 2018;25(1):R11–r29. doi: 10.1530/ERC-17-0269
   PubMed Web of Science ®Google Scholar
• Tsoli M, Koumarianou A, Angelousi A, et al. Established and novel circulating neuroendocrine tumor biomarkers for diagnostic, predictive and prognostic use. Best Pract Res Clin Endocrinol Metab. 2023;37(5):101785. doi: 10.1016/j.beem.2023.101785
   PubMed Web of Science ®Google Scholar
• Gut P, Ruchała M. Evaluation of 5-hydroxyindoloacetic acid excretion in urine in patients with small intestine neuroendocrine neoplasm and carcinoid syndrome treated with somatostatin analogues. Neuro Endocrinol Lett. 2019;40(7–8):315–8.
   PubMed Web of Science ®Google Scholar
• Hofland J, Falconi M, Christ E, et al. European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes. J Neuroendocrinol. 2023;35(8):e13318. doi: 10.1111/jne.13318
   PubMedGoogle Scholar
• La SA, Giuffrida D, Modica R. Editorial: neuroendocrine tumors: the road to precision medicine. Front Endocrinol. 2023;14:1253319. doi: 10.3389/fendo.2023.1253319
   PubMed Web of Science ®Google Scholar
• Fazio N, La Salvia A. Precision medicine in gastroenteropancreatic neuroendocrine neoplasms: where are we in 2023? Best Pract Res Clin Endocrinol Metab. 2023;37(5):101794. doi: 10.1016/j.beem.2023.101794
   PubMed Web of Science ®Google Scholar